What the ATTAIN-MAINTAIN trial tells us about GLP-1 maintenance

ATTAIN-MAINTAIN (NCT06584916) was a 52-week, randomized, double-blind, placebo-controlled Phase 3b trial. It enrolled 376 participants who had completed the SURMOUNT-5 head-to-head trial — all adults with obesity or overweight who had reached a weight plateau on either Wegovy or Zepbound.

Those participants were re-randomized in a 3:2 ratio to receive either orforglipron (titrated to 24 mg or 36 mg once daily) or placebo, alongside diet and physical activity guidance. The primary endpoint was whether orforglipron was superior to placebo in maintaining prior weight reduction at 52 weeks.

Orforglipron is a non-peptide, small-molecule GLP-1 receptor agonist. Unlike injectable semaglutide and tirzepatide, it can be taken as a daily pill at any time, without food or water restrictions — a meaningful practical difference from Rybelsus, the existing oral semaglutide approved for type 2 diabetes at lower doses.

Orforglipron met the primary endpoint, demonstrating superior weight maintenance versus placebo.

In the Wegovy-to-orforglipron group: participants maintained their previously achieved weight loss with an average difference of just 0.9 kg at 52 weeks. In the Zepbound-to-orforglipron group, the average difference was 5.0 kg — meaning most, but not all, of the prior loss was preserved.

At 24 weeks — the last data point before placebo participants became eligible for rescue therapy with orforglipron — the difference between groups was sharper. In the Wegovy arm, orforglipron participants showed a -0.1 kg change from their ATTAIN-MAINTAIN starting weight versus +9.4 kg in the placebo group. In the Zepbound arm, orforglipron participants showed +2.6 kg versus +9.1 kg in the placebo group.

Those placebo numbers matter: they show what weight regain looks like without continued GLP-1 therapy within the first six months of stopping.

What the trial doesn't tell us: ATTAIN-MAINTAIN was 52 weeks. There is no data beyond one year for this specific maintenance strategy. Participants were selected from SURMOUNT-5 — a U.S. trial with specific eligibility criteria. Results may not generalize to all GLP-1 patients or to those with type 2 diabetes. This was also a Phase 3b study; it was not the primary registration trial for orforglipron.

Orforglipron (brand name Foundayo) was FDA-approved on April 1, 2026 for chronic weight management in adults with obesity, or in adults with overweight who have at least one weight-related condition. Approval was granted under the FDA's National Priority Voucher program — the fastest approval of a new molecular entity since 2002. Foundayo is the first oral GLP-1 receptor agonist approved for weight loss, and the only one that can be taken any time of day without food or water restrictions.

Orforglipron's practical profile differs from existing oral GLP-1 options. Rybelsus (oral semaglutide 3–14 mg) requires dosing on an empty stomach with limited water, at least 30 minutes before eating. Orforglipron can be taken without food or timing restrictions — a meaningful real-world difference if approved.

The Wegovy pill (oral semaglutide 25 mg) is now FDA-approved for weight management, representing a different oral option from a different manufacturer.

Foundayo's FDA-approved label reflects the ATTAIN-1 weight-loss indication. Use as a step-down or maintenance therapy after injectable GLP-1s — the strategy ATTAIN-MAINTAIN tested — remains off-label pending further evidence and label updates. Long-term maintenance data beyond 52 weeks do not yet exist for this step-down strategy.

The safety profile in ATTAIN-MAINTAIN was consistent with other orforglipron trials: gastrointestinal adverse events were most common, generally mild to moderate. No hepatic safety signal was observed. Discontinuation rates due to adverse events were low in both orforglipron and placebo groups.

• Should I have a maintenance plan in place before I reach my goal weight — not after?
• If I want to consider stepping down from an injectable to an oral GLP-1 in the future, what options are available or likely to become available?
• How is my body responding to my current medication, and what does that tell us about how I might maintain results long-term?
• What is my plan if I regain weight after stopping or changing medication?

• Your weight at the point you reach plateau on your current medication — this is your baseline for any maintenance conversation
• New oral GLP-1 approvals from the FDA, since the pipeline is moving quickly
• Foundayo (orforglipron) prescribing updates and any future label expansions covering maintenance or step-down use

The strongest takeaway from ATTAIN-MAINTAIN may not be about orforglipron specifically. It's about timing. The trial enrolled people who had already plateaued. The research question — what comes after your injectable GLP-1 — is one your prescriber may not raise unless you do.

Weight maintenance is a clinical problem, not a product one. Foundayo (orforglipron) is now one option. The Wegovy pill is another. Your situation, insurance coverage, side effect history, and treatment goals will shape which makes sense. That conversation starts now, not at goal weight.

prnewswire.com

clinicaltrials.gov

pubmed.ncbi.nlm.nih.gov